U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H12F6N6O
Molecular Weight 442.3186
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of VERDINEXOR

SMILES

c1ccnc(c1)NN=C(/C(/[H])=C(/[H])\n2cnc(-c3cc(cc(c3)C(F)(F)F)C(F)(F)F)n2)O

InChI

InChIKey=OPAKEJZFFCECPN-XQRVVYSFSA-N
InChI=1S/C18H12F6N6O/c19-17(20,21)12-7-11(8-13(9-12)18(22,23)24)16-26-10-30(29-16)6-4-15(31)28-27-14-3-1-2-5-25-14/h1-10H,(H,25,27)(H,28,31)/b6-4-

HIDE SMILES / InChI

Molecular Formula C18H12F6N6O
Molecular Weight 442.3186
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Verdinexor (KPT-335) is a small-molecule selective inhibitor of nuclear export (SINE). Karyopharm Therapeutics has recently developed first-in-class, novel SINE compounds using molecular modeling to screen a small virtual library of compounds against the NES groove of human exportin-1 (XPO1). These compounds inhibit nuclear-cytoplasmic export by reversibly binding to the cargo recognition site of XPO1 and are orally bioavailable. Verdinexor was shown to potently and selectively inhibit vRNP export and effectively inhibited the replication of various influenza virus A and B strains in vitro, including pandemic H1N1 virus, highly pathogenic H5N1 avian influenza virus, and the recently emerged H7N9 strain. Verdinexor is in development for the treatment of viral indications. Verdinexor is being evaluated for the treatment of lymphomas in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

PubMed

PubMed

TitleDatePubMed
Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.
2014 Sep 1
Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection.
2016
Patents

Sample Use Guides

A Phase 1, randomized, double-blind, placebo-controlled, sequential, dose-escalating (5-100 mg) trial was conducted to evaluate the safety and tolerability of oral Verdinexor (KPT-335) in healthy adult subjects
Route of Administration: Oral
Verdinexor was found to have good efficacy against the influenza A and B virus strains tested in the nanomolar range (SI of 99), except against the emerging A/Anhui/1/2013 (H7N9) strain, against which it showed some but limited efficacy (SI of 64).
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:29:16 UTC 2021
Edited
by admin
on Sat Jun 26 06:29:16 UTC 2021
Record UNII
85Q03215IW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VERDINEXOR
INN   USAN  
INN   USAN  
Official Name English
VERDINEXOR [INN]
Common Name English
(2Z)-3-(3-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-1H-1,2,4-TRIAZOL-1-YL)-N'-(PYRIDIN-2-YL)PROP-2-ENEHYDRAZIDE
Systematic Name English
2-PROPENOIC ACID, 3-(3-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-1H-1,2,4-TRIAZOL-1-YL)-, 2-(2-PYRIDINYL)HYDRAZIDE, (2Z)-
Systematic Name English
KPT-335
Code English
VERDINEXOR [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C281
Created by admin on Sat Jun 26 06:29:16 UTC 2021 , Edited by admin on Sat Jun 26 06:29:16 UTC 2021
Code System Code Type Description
PUBCHEM
71492799
Created by admin on Sat Jun 26 06:29:16 UTC 2021 , Edited by admin on Sat Jun 26 06:29:16 UTC 2021
PRIMARY
INN
9873
Created by admin on Sat Jun 26 06:29:16 UTC 2021 , Edited by admin on Sat Jun 26 06:29:16 UTC 2021
PRIMARY
CAS
1656285-28-7
Created by admin on Sat Jun 26 06:29:16 UTC 2021 , Edited by admin on Sat Jun 26 06:29:16 UTC 2021
NON-SPECIFIC STEREOCHEMISTRY
FDA UNII
85Q03215IW
Created by admin on Sat Jun 26 06:29:16 UTC 2021 , Edited by admin on Sat Jun 26 06:29:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL3545187
Created by admin on Sat Jun 26 06:29:16 UTC 2021 , Edited by admin on Sat Jun 26 06:29:16 UTC 2021
PRIMARY
NCI_THESAURUS
C152860
Created by admin on Sat Jun 26 06:29:16 UTC 2021 , Edited by admin on Sat Jun 26 06:29:16 UTC 2021
PRIMARY
DRUG BANK
DB12207
Created by admin on Sat Jun 26 06:29:16 UTC 2021 , Edited by admin on Sat Jun 26 06:29:16 UTC 2021
PRIMARY
CAS
1392136-43-4
Created by admin on Sat Jun 26 06:29:16 UTC 2021 , Edited by admin on Sat Jun 26 06:29:16 UTC 2021
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
INHIBITOR->TARGET ORGANISM
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY